Haemonetics Corporation
Last updated September 27, 2026
Organization details
- Legal name
- Haemonetics Corporation
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- HAE
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000313143
Board of directors
-
Charles J. Dockendorff · DirectorSince 2023
-
Christopher Simon · Director · President & CEOSince 2023
-
Claire Pomeroy · DirectorSince 2023
-
Diane M. Bryant · DirectorSince 2023
- Since 2023
-
Lloyd Emerson Johnson · DirectorSince 2023
-
Mark W. Kroll · DirectorSince 2023
- Since 2026
-
Michael J. Coyle · DirectorSince 2023
-
Robert E. Abernathy · DirectorSince 2023
Chief executives
Christopher Simon
· President & CEO
Dates unknown
Director election results
Annual meeting of July 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.4%
-
98.5%
-
98.5%
-
98.5%
-
99.5%
-
99.5%
-
99.6%
-
99.7%
Board connections
10 of this board's directors also sit on 18 other boards.
- via Ellen M. Zane and Martin D. Madaus
- via Charles J. Dockendorff and Ellen M. Zane
- via Lloyd Emerson Johnson
- via Robert E. Abernathy
- via Mark W. Kroll
- via Lloyd Emerson Johnson
- via Diane M. Bryant
- via Claire Pomeroy
- via Ellen M. Zane
- via Michael J. Coyle
- via Diane M. Bryant
- via Charles J. Dockendorff
- via Martin D. Madaus
- via Martin D. Madaus
- via Christopher Simon
- via Martin D. Madaus
- via Ellen M. Zane
- via Lloyd Emerson Johnson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $98,784
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 2026 | Robert E. Abernathy Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Diane M. Bryant Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Michael J. Coyle Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Lloyd Emerson Johnson Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Mark W. Kroll Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Claire Pomeroy Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Ellen M. Zane Director | Grant or award | +2,538 | — | — |
| Jul 24, 2026 | Martin D. Madaus Director | Grant or award | +2,538 | — | — |
| Jun 5, 2026 | Maunsell Farris Maryanne Officer (VP, Chief Accounting Officer) | Shares withheld for tax | −259 | $71.28 | $18,462 |
| Jun 5, 2026 | Miller Laurie A. Officer (SVP, Human Resources) | Shares withheld for tax | −313 | $71.28 | $22,311 |
| May 15, 2026 | Basil Michelle L Officer (EVP and General Counsel) | Shares withheld for tax | −2,913 | $56.29 | $163,973 |
| May 15, 2026 | Chan Frank Officer (EVP, Chief Operating Officer) | Shares withheld for tax | −546 | $56.29 | $30,734 |
| May 15, 2026 | James DArecca Officer (EVP, Chief Financial Officer) | Shares withheld for tax | −2,505 | $56.29 | $141,006 |
| May 15, 2026 | Maunsell Farris Maryanne Officer (VP, Chief Accounting Officer) | Shares withheld for tax | −197 | $56.29 | $11,089 |
| May 15, 2026 | Galvin Roy Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −879 | $56.29 | $49,479 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.